Northwest Biotherapeutics Inc. can proceed with claims against seven firms including Citadel Securities and Virtu Americas LLC for depressing the company’s stock price through false sale orders, a ...

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the ...

The month of July saw $37.3 billion in trading volume for stocks that trade on the OTCQK and OTCQB. While some of the stocks that trade over-the-counter are considered penny stocks based on their ...

Find the latest Northwest Biotherapeutics, Inc. NWBO analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Investors in Northwest Biotherapeutics are anxiously awaiting a decision from the UK’s MHRA regarding the approval of DCVax-L, a treatment for glioblastoma (brain cancer) that has also shown ...

A brain cancer immunotherapy being developed by US company Northwest Biotherapeutics (NW Bio) is the first drug to be approved for early access under the UK's new fast-track programme. NW Bio's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

There are no SEC filings that match your filter(s), please update your selections to return more records. Nasdaq provides company’s SEC filings, which are financial statements and reports filed ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual ...